Materialise NV (MTLS) Q2 2025 Earnings Call Transcript
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 24 2025
0mins
Should l Buy MTLS?
Source: SeekingAlpha
Total consolidated revenue EUR 64.8 million, a decrease of 5.8% year-over-year. The decline was due to intensified geopolitical and macroeconomic turbulence, as well as the unfavorable effect of a weaker U.S. dollar.
Gross profit margin 58.3%, an increase from 57% in Q2 2024. This improvement was attributed to changes in the revenue mix and optimization of direct production costs despite inflationary pressures.
Adjusted EBIT EUR 3.1 million, down from EUR 3.9 million in Q2 2024. The decrease was due to lower revenue, but targeted cost control measures helped mitigate the impact.
Net result Profit of EUR 0.2 million, despite being negatively impacted by large unfavorable effects from exchange rate fluctuations.
Free cash flow Positive for the first half of 2025, leading to a net cash position of EUR 63 million at the end of Q2, an increase of EUR 2 million compared to the beginning of the year.
Materialise Medical revenue Increased by almost 17% year-over-year, driven by 14% growth in Medical Software and 18% growth in Medical Devices sales. This was attributed to continued growth in direct and partner sales.
Materialise Software revenue Decreased by 12% year-over-year to EUR 9.9 million. The decline was due to the transition to a recurring revenue model, macroeconomic uncertainty, and unfavorable foreign exchange rates.
Materialise Manufacturing revenue Decreased by almost 25% year-over-year to EUR 22.1 million. The decline was driven by geopolitical uncertainty and macroeconomic headwinds, particularly in the Automotive segment.
Adjusted EBITDA for Materialise Medical EUR 10.7 million, with an increased adjusted EBITDA margin of 32.7%, reflecting strong revenue growth and planned R&D investments.
Adjusted EBITDA for Materialise Software EUR 1.4 million, representing a stable adjusted EBITDA margin of 14%, despite lower revenue due to effective cost management.
Adjusted EBITDA for Materialise Manufacturing Negative EUR 0.8 million, slightly below the result of the first quarter of 2025, but significantly improved from the last quarter of 2024. The improvement was due to cost control and a focus on strategic areas.
Gross profit EUR 37.8 million, representing a gross profit margin of 58.3%, up from 57% in Q2 2024. The increase was due to mix effects and production efficiencies.
Operating expenses Decreased by close to 1% year-over-year, with R&D expenses remaining flat and reductions in sales, marketing, and G&A expenses due to cost optimizations.
Net financial result Loss of EUR 3.1 million, including a significant negative impact from foreign exchange fluctuations of minus EUR 3.3 million.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MTLS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MTLS
About MTLS
Materialise NV is a Belgium-based company that is engaged in the software industry. The Company is a provider of software and three-dimensional (3D) printing services that incorporates 3D printing experience into a wide range of software solutions and 3D printing services. It transforms businesses with three elements of align: quality, reliability, and repeatability through which it forms the backbone of the 3D printing industry. The solutions are built 3D printing applications in several industries, including healthcare, automotive, aerospace, art and design, and consumer goods. It also operates in the domestic market and worldwide, including Colombia, Brazil, Australia, Malaysia, China, Japan, Austria, Poland, Germany, and France, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Materialise Transfers RapidFit Business to Management Team
- Increased Business Independence: Materialise's decision to transfer the RapidFit business to its management team allows it to operate as an independent company, enhancing market flexibility and customer focus, with the transaction expected to close around April 30, 2026.
- Core Business Focus: This move aligns with Materialise's growth strategy by concentrating investments and resources on the most promising business lines while enabling RapidFit to leverage its core strengths to drive global growth.
- Technological Advantage Utilization: RapidFit specializes in delivering custom 3D-printed jigs and quality control solutions for the automotive and manufacturing sectors, utilizing advanced additive manufacturing technologies to improve production efficiency, reduce lead times, and support quality assurance processes.
- Stable Customer Impact: The transaction is not expected to affect existing customer orders or ongoing projects, ensuring that RapidFit can maintain continuity in customer service after becoming independent.
See More
Materialise NV Q4 2025 Earnings Call Highlights
- Dual Listing Advantage: Materialise NV completed its dual listing on Euronext Brussels, which, while not raising capital, broadens its European investor base and enhances operational flexibility, potentially paving the way for future ADS or share buyback initiatives.
- Share Buyback Implementation: The company announced a share buyback program of up to EUR 30 million, having already repurchased 187,500 shares for nearly USD 1 million, demonstrating a commitment to shareholder value and market confidence.
- Medical Business Growth: The Medical segment treated over 17,000 patients in 2025, surpassing a cumulative total of 700,000 patients, with expectations for continued double-digit growth, solidifying its position as a key growth driver for the company.
- Strong Financial Performance: In Q4 2025, revenue grew by 6.8% year-on-year to EUR 70.2 million, with a gross profit margin of 58.1% and adjusted EBIT of EUR 4 million, reflecting ongoing improvements in cost control and profitability.
See More
Materialise Q4 Earnings Beat Expectations with Strong Revenue Growth
- Earnings Highlights: Materialise reported a GAAP EPS of $0.12 for Q4 2025, with revenue of $82.44 million exceeding expectations by $0.42 million and reflecting a year-over-year growth of 6.8%, indicating robust market performance.
- Adjusted EBITDA Growth: The adjusted EBITDA for Q4 increased significantly to 9,524 kEUR from 4,306 kEUR in 2024, showcasing a marked improvement in profitability and reflecting enhanced operational efficiency.
- Free Cash Flow Performance: The free cash flow for Q4 2025 was 4,511 kEUR, down from 6,218 kEUR in 2024, yet still demonstrating solid cash flow management that supports future investments.
- Future Outlook: The company anticipates full-year revenues for 2026 to grow to a range of 273,000 to 283,000 kEUR, with continued investments in its Medical and Software segments while maintaining cost discipline, projecting adjusted EBIT of 10,000 to 12,000 kEUR, indicating strong growth potential.
See More
Materialise NV Reports Strong Q4 and Full Year 2025 Financial Results
- Significant Revenue Growth: Total revenue for Q4 2025 reached €70.164 million, a 6.8% increase year-over-year, demonstrating strong performance in the medical device sector, particularly with a 16.3% rise in medical segment revenue to €37.016 million, further solidifying market leadership.
- Improved Profitability: Adjusted EBITDA for Q4 2025 surged to €9.524 million from €4.306 million in the same period of 2024, reflecting successful cost control and operational efficiency, which is expected to enhance investor confidence.
- Robust Cash Flow: As of December 31, 2025, the company reported €133.918 million in cash and cash equivalents, with a net cash position improving to €70.805 million, indicating strong financial health and the ability to continue investing in R&D and market expansion.
- Optimistic Future Outlook: The company anticipates full-year revenues for 2026 to range between €273,000 and €283,000, with continued strong growth in the medical segment and a transition to a cloud-based subscription model in the software segment, showcasing proactive positioning for future market opportunities.
See More
Materialise NV Reports Strong Q4 and Full Year 2025 Financial Results
- Q4 Revenue Growth: Total revenue for Q4 2025 reached €70,164k, a 6.8% increase year-over-year, with the Medical segment growing 16.3% to €37,016k, highlighting strong demand in the healthcare market and reinforcing the company's leadership in 3D-printed medical devices.
- Gross Margin Improvement: The gross margin for Q4 2025 rose to 58.1%, up from 55.4% in Q4 2024, reflecting successful cost control and operational efficiency, which enhances overall profitability.
- Significant Net Profit Increase: Net profit for Q4 2025 was €6,206k, a substantial rise from €2,907k in Q4 2024, indicating a marked improvement in profitability and market performance, boosting investor confidence.
- Strong Cash Reserves: As of December 31, 2025, the company reported cash and cash equivalents of €133,918k, significantly up from €102,304k in 2024, demonstrating a robust financial position that provides ample funding for future investments and innovation.
See More
Materialise to Announce Q4 Earnings on February 19
- Earnings Announcement: Materialise is set to release its Q4 earnings on February 19 before the market opens, with expectations that the results will significantly impact stock price movements.
- Earnings Expectations: The consensus EPS estimate stands at $0.07, and achieving this target would positively reflect the company's profitability and bolster market confidence in its growth trajectory.
- Revenue Forecast: Analysts estimate revenue at $82.02 million, and meeting this expectation could enhance Materialise's competitive position in the industry while attracting increased investor interest.
- Historical Performance Review: Over the past year, Materialise has exceeded EPS estimates 50% of the time and revenue estimates 75% of the time, indicating a stable performance and growth potential in the market.
See More
Materialise Transfers RapidFit Business to Management Team
- Increased Business Independence: Materialise's decision to transfer the RapidFit business to its management team allows it to operate as an independent company, enhancing market flexibility and customer focus, with the transaction expected to close around April 30, 2026.
- Core Business Focus: This move aligns with Materialise's growth strategy by concentrating investments and resources on the most promising business lines while enabling RapidFit to leverage its core strengths to drive global growth.
- Technological Advantage Utilization: RapidFit specializes in delivering custom 3D-printed jigs and quality control solutions for the automotive and manufacturing sectors, utilizing advanced additive manufacturing technologies to improve production efficiency, reduce lead times, and support quality assurance processes.
- Stable Customer Impact: The transaction is not expected to affect existing customer orders or ongoing projects, ensuring that RapidFit can maintain continuity in customer service after becoming independent.
See More
Materialise NV Q4 2025 Earnings Call Highlights
- Dual Listing Advantage: Materialise NV completed its dual listing on Euronext Brussels, which, while not raising capital, broadens its European investor base and enhances operational flexibility, potentially paving the way for future ADS or share buyback initiatives.
- Share Buyback Implementation: The company announced a share buyback program of up to EUR 30 million, having already repurchased 187,500 shares for nearly USD 1 million, demonstrating a commitment to shareholder value and market confidence.
- Medical Business Growth: The Medical segment treated over 17,000 patients in 2025, surpassing a cumulative total of 700,000 patients, with expectations for continued double-digit growth, solidifying its position as a key growth driver for the company.
- Strong Financial Performance: In Q4 2025, revenue grew by 6.8% year-on-year to EUR 70.2 million, with a gross profit margin of 58.1% and adjusted EBIT of EUR 4 million, reflecting ongoing improvements in cost control and profitability.
See More
Materialise Q4 Earnings Beat Expectations with Strong Revenue Growth
- Earnings Highlights: Materialise reported a GAAP EPS of $0.12 for Q4 2025, with revenue of $82.44 million exceeding expectations by $0.42 million and reflecting a year-over-year growth of 6.8%, indicating robust market performance.
- Adjusted EBITDA Growth: The adjusted EBITDA for Q4 increased significantly to 9,524 kEUR from 4,306 kEUR in 2024, showcasing a marked improvement in profitability and reflecting enhanced operational efficiency.
- Free Cash Flow Performance: The free cash flow for Q4 2025 was 4,511 kEUR, down from 6,218 kEUR in 2024, yet still demonstrating solid cash flow management that supports future investments.
- Future Outlook: The company anticipates full-year revenues for 2026 to grow to a range of 273,000 to 283,000 kEUR, with continued investments in its Medical and Software segments while maintaining cost discipline, projecting adjusted EBIT of 10,000 to 12,000 kEUR, indicating strong growth potential.
See More
Materialise NV Reports Strong Q4 and Full Year 2025 Financial Results
- Significant Revenue Growth: Total revenue for Q4 2025 reached €70.164 million, a 6.8% increase year-over-year, demonstrating strong performance in the medical device sector, particularly with a 16.3% rise in medical segment revenue to €37.016 million, further solidifying market leadership.
- Improved Profitability: Adjusted EBITDA for Q4 2025 surged to €9.524 million from €4.306 million in the same period of 2024, reflecting successful cost control and operational efficiency, which is expected to enhance investor confidence.
- Robust Cash Flow: As of December 31, 2025, the company reported €133.918 million in cash and cash equivalents, with a net cash position improving to €70.805 million, indicating strong financial health and the ability to continue investing in R&D and market expansion.
- Optimistic Future Outlook: The company anticipates full-year revenues for 2026 to range between €273,000 and €283,000, with continued strong growth in the medical segment and a transition to a cloud-based subscription model in the software segment, showcasing proactive positioning for future market opportunities.
See More
Materialise NV Reports Strong Q4 and Full Year 2025 Financial Results
- Q4 Revenue Growth: Total revenue for Q4 2025 reached €70,164k, a 6.8% increase year-over-year, with the Medical segment growing 16.3% to €37,016k, highlighting strong demand in the healthcare market and reinforcing the company's leadership in 3D-printed medical devices.
- Gross Margin Improvement: The gross margin for Q4 2025 rose to 58.1%, up from 55.4% in Q4 2024, reflecting successful cost control and operational efficiency, which enhances overall profitability.
- Significant Net Profit Increase: Net profit for Q4 2025 was €6,206k, a substantial rise from €2,907k in Q4 2024, indicating a marked improvement in profitability and market performance, boosting investor confidence.
- Strong Cash Reserves: As of December 31, 2025, the company reported cash and cash equivalents of €133,918k, significantly up from €102,304k in 2024, demonstrating a robust financial position that provides ample funding for future investments and innovation.
See More
Materialise to Announce Q4 Earnings on February 19
- Earnings Announcement: Materialise is set to release its Q4 earnings on February 19 before the market opens, with expectations that the results will significantly impact stock price movements.
- Earnings Expectations: The consensus EPS estimate stands at $0.07, and achieving this target would positively reflect the company's profitability and bolster market confidence in its growth trajectory.
- Revenue Forecast: Analysts estimate revenue at $82.02 million, and meeting this expectation could enhance Materialise's competitive position in the industry while attracting increased investor interest.
- Historical Performance Review: Over the past year, Materialise has exceeded EPS estimates 50% of the time and revenue estimates 75% of the time, indicating a stable performance and growth potential in the market.
See More
